2. Search Result
Search Result
Results for "

Cardioprotection

" in MedChemExpress (MCE) Product Catalog:

23

Inhibitors & Agonists

2

Peptides

5

Natural
Products

1

Isotope-Labeled Compounds

Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-N0520
    Calycosin-7-O-β-D-glucoside
    2 Publications Verification

    Calycosin-7-glucoside

    		 Reactive Oxygen Species Others
    Calycosin-7-O-β-D-glucoside is an isoflavone isolated from Astragali Radix. Calycosin-7-O-β-D-glucoside has variety of biological activities, such as neuroprotective, cardioprotection, anti-inflammation, and antioxidative stress effects .
    Calycosin-7-O-β-D-glucoside
  • HY-F0004
    β-Nicotinamide mononucleotide
    Maximum Cited Publications
    11 Publications Verification

    β-NM; NMN

    		 Endogenous Metabolite Neurological Disease Cancer
    β-nicotinamide mononucleotide (β-NM) is a product of the nicotinamide phosphoribosyltransferase (NAMPT) reaction and a key NAD + intermediate. The pharmacological activities of β-nicotinamide mononucleotide include its role in cellular biochemical functions, cardioprotection, diabetes, Alzheimer's disease, and complications associated with obesity .
    β-Nicotinamide mononucleotide
  • HY-103346
    MMPSI

    		Caspase Apoptosis Cardiovascular Disease
    MMPSI is a potent and selective small molecule caspase 3 and caspase 7 inhibitor with an IC50 of 1.7 μM for human caspase-3. MMPSI can significantly reduce ischemia-reperfusion-induced infarct size in the isolated rabbit heart, and reduce apoptosis in both the ischemic myocardium and isolated cardiomyocytes. MMPSI can be used for researching cardioprotection .
    MMPSI
  • HY-N0615
    Notoginsenoside R1
    2 Publications Verification

    Sanchinoside R1; Sanqi glucoside R1

    		 Amyloid-β Apoptosis Others
    Notoginsenoside R1 (Sanchinoside R1), a saponin, is isolated from P. notoginseng. Notoginsenoside R1 exhibits anti-oxidation, anti-inflammatory, anti-angiogenic, and anti-apoptosis activities. Notoginsenoside R1 provides cardioprotection against ischemia/reperfusion (I/R) injury. Notoginsenoside R1 also provides neuroprotection in H2O2-induced oxidative damage in PC12 cells .
    Notoginsenoside R1
  • HY-153392
    TYA-018

    		Oxidative Phosphorylation HDAC Cardiovascular Disease
    TYA-018 is an orally active, potent and highly selective HDAC6 inhibitor. TYA-018 can protect heart function in mice. TYA-018 also enhances energetics in mice by increasing expression of targets associated with fatty acid metabolism, protein metabolism, and oxidative phosphorylation .
    TYA-018
  • HY-B1392A
    Esmolol

    		Adrenergic Receptor Cardiovascular Disease
    Esmolol is a potent and cardio-selective β-adrenergic blocker. Esmolol shows cardioprotection. Esmolol has the potential for the research of tachycardia with ischemic heart disease .
    Esmolol
  • HY-128090
    Apstatin

    		Aminopeptidase Cardiovascular Disease
    Apstatin is a potent aminopeptidase P (APP) inhibitor with Ki values of 2.6, 0.64 µM for rat and human APP, respectively. Apstatin shows cardioprotection .
    Apstatin
  • HY-19463A
    F15845

    		Sodium Channel Cardiovascular Disease
    F 15845 is a highly effective persistent sodium current blocker. F 15845 also is a cardioprotective agent, has anti-ischemic activity and exerts short- and long-term cardioprotection after myocardial infarction. F 15845 can be used for the research of myocardium functional impairment .
    F15845
  • HY-N0520R
    Calycosin-7-O-β-D-glucoside (Standard)

    		Reactive Oxygen Species Others
    Calycosin-7-O-β-D-glucoside (Standard) is the analytical standard of Calycosin-7-O-β-D-glucoside. This product is intended for research and analytical applications. Calycosin-7-O-β-D-glucoside is an isoflavone isolated from Astragali Radix. Calycosin-7-O-β-D-glucoside has variety of biological activities, such as neuroprotective, cardioprotection, anti-inflammation, and antioxidative stress effects .
    Calycosin-7-O-β-D-glucoside (Standard)
  • HY-N0615R
    Notoginsenoside R1 (Standard)

    		Amyloid-β Apoptosis Others
    Notoginsenoside R1 (Standard) is the analytical standard of Notoginsenoside R1. This product is intended for research and analytical applications. Notoginsenoside R1 (Sanchinoside R1), a saponin, is isolated from P. notoginseng. Notoginsenoside R1 exhibits anti-oxidation, anti-inflammatory, anti-angiogenic, and anti-apoptosis activities. Notoginsenoside R1 provides cardioprotection against ischemia/reperfusion (I/R) injury. Notoginsenoside R1 also provides neuroprotection in H2O2-induced oxidative damage in PC12 cells .
    Notoginsenoside R1 (Standard)
  • HY-F0004S
    β-Nicotinamide mononucleotide-d4

    β-NM-d4; NMN-d4

    		 Endogenous Metabolite Neurological Disease Cancer
    β-Nicotinamide mononucleotide-d4 is the deuterium labeled β-Nicotinamide mononucleotide. β-nicotinamide mononucleotide (β-NM) is a product of the nicotinamide phosphoribosyltransferase (NAMPT) reaction and a key NAD+ intermediate. The pharmacological activities of β-nicotinamide mononucleotide include its role in cellular biochemical functions, cardioprotection, diabetes, Alzheimer's disease, and complications associated with obesity[1].
    β-Nicotinamide mononucleotide-d4
  • HY-P3101
    GLP-1(28-36)amide

    		GCGR Cardiovascular Disease Metabolic Disease
    GLP-1(28-36)amide, a C-terminal nonapeptide of GLP-1, is a major product derived from the cleavage of GLP-1 by the neutral endopeptidase (NEP). GLP-1(28-36)amide is an antioxidant and targets to mitochondrion, inhibits mitochondrial permeability transition (MPT). GLP-1(28-36)amide has anti-diabetic and cardioprotection effects .
    GLP-1(28-36)amide
  • HY-108573
    P-1075
    1 Publications Verification

    		 Potassium Channel Cardiovascular Disease
    P-1075 is a potent activator of sulfonylurea receptor 2-associated ATP-sensitive potassium channels (SUR2-KIR6), with an EC50 value of 45 nM for SUR2B-KIR6 channel activation . P-1075 also P1075 opens mitochondrial K(ATP) channels and generates reactive oxygen species resulting in cardioprotection of rabbit hearts .
    P-1075
  • HY-P3101A
    GLP-1(28-36)amide TFA

    		GCGR Cardiovascular Disease Metabolic Disease
    GLP-1(28-36)amide TFA, a C-terminal nonapeptide of GLP-1, is a major product derived from the cleavage of GLP-1 by the neutral endopeptidase (NEP). GLP-1(28-36)amide TFA is an antioxidant and targets to mitochondrion, inhibits mitochondrial permeability transition (MPT). GLP-1(28-36)amide TFA has anti-diabetic and cardioprotection effects .
    GLP-1(28-36)amide TFA
  • HY-105064
    Zoniporide
    1 Publications Verification

    CP-597396

    		 Na+/H+ Exchanger (NHE) Cardiovascular Disease
    Zoniporide (CP-597396) is a potent and selective NHE-1 inhibitor with cardioprotective activity. Zoniporide inhibits 22Na + uptake by human NHE-1-expressing fibroblasts in a concentration-dependent manner (IC50=14 nM). Zoniporide inhibits platelet swelling in vitro with an IC50 of 0.059 μM. Zoniporide can be used in the study of cardiovascular disease .
    Zoniporide
  • HY-105064D
    Zoniporide hydrochloride hydrate
    1 Publications Verification

    CP-597396 hydrochloride hydrate

    		 Na+/H+ Exchanger (NHE) Cardiovascular Disease
    Zoniporide (CP-597396) hydrochloride hydrate is a potent and selective inhibitor of sodium-hydrogen exchanger type 1 (NHE-1). Zoniporide hydrochloride hydrate inhibits human NHE-1 (IC50=14 nM), and has >150-fold selectivity versus other NHE isoforms. Zoniporide hydrochloride hydrate potently inhibits ex vivo NHE-1-dependent swelling of human platelets (IC50=59 nM) .
    Zoniporide hydrochloride hydrate
  • HY-105064B
    Zoniporide hydrochloride

    CP-597396 hydrochloride

    		 Na+/H+ Exchanger (NHE) Cardiovascular Disease
    Zoniporide (CP-597396) hydrochloride is a potent and selective inhibitor of sodium-hydrogen exchanger type 1 (NHE-1). Zoniporide hydrochloride inhibits human NHE-1 (IC50=14 nM), and has >150-fold selectivity versus other NHE isoforms. Zoniporide hydrochloride potently inhibits ex vivo NHE-1-dependent swelling of human platelets (IC50=59 nM) .
    Zoniporide hydrochloride
  • HY-121586
    Nafazatrom

    Bay g 6575

    		 Others Cardiovascular Disease
    Nafazatrom (Bay g 6575) is an orally active cardioprotective agent that protects against ischemic damage. Nafazatrom dose-dependently inhibits neutrophil aggregation, superoxide anion generation, arachidonic acid metabolism, and to a lesser extent the release of β-glucosidase, platelet aggregation or arachidonic acid in vitro. Acid metabolism has no significant effect. In a dog ischemia-reperfusion model, Nafazatrom (10 mg/kg; po) reduced infarct size and the occurrence of arrhythmias and rescued ischemic myocardial function without affecting any hemodynamic changes. The basis of Nafazatrom's cardioprotection may be inhibition of neutrophil function and cellular infiltration in vitro .
    Nafazatrom
  • HY-135746
    OR-1896
    1 Publications Verification

    		 Potassium Channel Phosphodiesterase (PDE) Drug Metabolite Apoptosis Cardiovascular Disease
    OR-1896 is an active long-lived metabolite of Levosimendan. OR-1896 is a highly selective phosphodiesterase (PDE) III isoform inhibitor and a powerful vasodilator. OR-1896 can open ATP-sensitive K + channels and has Ca 2+-sensitizing effect. OR-1896 mitigates cardiomyocyte apoptosis, cardiac remodeling and myocardial inflammation .
    OR-1896
  • HY-19310
    AMP-579

    		Adenosine Receptor Cardiovascular Disease Metabolic Disease
    AMP-579 is an adenosine receptor agonist that primarily targets adenosine A1 and A2A receptors (with Ki values of 1.7 and 4.5 nM for the A1 receptor in rat brain and adipocytes, and a Ki value of 56 nM for the A2A receptor in rat brain). AMP-579 inhibits lipolysis, restores insulin-dependent glucose transport, and reduces heart rate through the activation of A1 receptors, while it induces vasodilation, particularly in coronary arteries, through the activation of A2A receptors (with an IC50 of 0.3 μM in porcine coronary arterial rings). AMP 579 shows potential for application in cardioprotection and the treatment of acute myocardial infarction .
    AMP-579
  • HY-14994
    SCH79797 dihydrochloride
    1 Publications Verification

    		 Protease Activated Receptor (PAR) Apoptosis Cardiovascular Disease
    SCH79797 dihydrochloride is a highly potent, selective nonpeptide protease activated receptor 1 (PAR1) antagonist. SCH79797 dihydrochloride inhibits binding of a high-affinity thrombin receptor-activating peptide to PAR1 with an IC50 of 70 nM and a Ki of 35 nM. SCH79797 dihydrochloride inhibits thrombin-induced platelet aggregation with an IC50 of 3 μM. SCH79797 dihydrochloride has antiproliferative and pro-apoptotic effects, and limits myocardial ischemia/reperfusion injury in rat hearts. SCH79797 dihydrochloride also potently prevents PAR1 activation in vascular smooth muscle cells, endothelial cells, and astrocytes .
    SCH79797 dihydrochloride
  • HY-14993
    SCH79797
    1 Publications Verification

    		 Protease Activated Receptor (PAR) Apoptosis Cardiovascular Disease
    SCH79797 is a highly potent, selective nonpeptide protease activated receptor 1 (PAR1) antagonist. SCH79797 inhibits binding of a high-affinity thrombin receptor-activating peptide to PAR1 with an IC50 of 70 nM and a Ki of 35 nM. SCH79797 inhibits thrombin-induced platelet aggregation with an IC50 of 3 μM. SCH79797 has antiproliferative and pro-apoptotic effects, and limits myocardial ischemia/reperfusion injury in rat hearts. SCH79797 also potently prevents PAR1 activation in vascular smooth muscle cells, endothelial cells, and astrocytes .
    SCH79797
  • HY-117970
    MMPI-1154

    		MMP Cardiovascular Disease
    MMPI-1154 is a promising novel cardio-cytoprotective imidazole-carboxylic acid (ICA) MMP-2 inhibitor(IC50=6.6 μM) and can be used for the study of acute myocardial infarction. MMPI-1154 also inhibits the activity of MMP-13, MMP-1 and MMP-9 with IC50s of 1.8 μM,10 μM, and 13 μM, respectively .
    MMPI-1154

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: